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Androgen receptor (AR)-mediated gene regulation involves
interactions with coregulatory proteins that include the mela-
noma antigen gene protein-A11 (MAGE-11). To understand the
functional significance of sequence similarity between MAGE-
11 and the adenovirus early protein E1A, we determined
whether MAGE-11 contributes to AR transcriptional activity
through an interaction with p300, a potent and ubiquitous tran-
scriptional regulator. Here, we report that MAGE-11 interacts
with the NH2-terminal region of p300 through the MAGE-11
MXXIF motif 185MXXIF189, with transcriptional activity de-
pending on the MAGE-11 F-box and MAPK phosphorylation.
The MAGE-11- and p300-dependent increase in AR transacti-
vation required theNH2-terminal regions of AR and p300, p300
acetyltransferase activity, and the AR FXXLF motif 23FQNLF27
interaction with MAGE-11. MAGE-11 linked AR to p300 and
the p160 coactivator, transcriptional intermediary protein 2
(TIF2). The p300 NH2-terminal FXXLF motif 33FGSLF37 was
required for transcriptional activation by TIF2. Increased
expression of p300 decreased the ubiquitinylation of MAGE-11
and transiently increased endogenous MAGE-11 levels. Auto-
acetylation of p300 and decreased acetylation of TIF2 were evi-
dent in the MAGE-11, p300, and TIF2 complex. The studies
suggest that MAGE-11 links NH2-terminal domains of AR and
p300 to promote transcriptional synergy through a cadre of
FXXLF-related interacting motifs.
The androgen receptor (AR)3 regulates gene transcription
required for male sex development by binding androgens with
high affinity and interacting with coregulatory proteins. AR
transcriptional activity derives fromactivation function 1 (AF1)
in the NH2-terminal region and the activation function 2 (AF2)
hydrophobic surface in the ligand binding domain (Fig. 1). AR
AF2 interacts with p160 coactivator LXXLL motifs and the AR
NH2-terminal FXXLF motif 23FQNLF27 that mediates the
androgen-dependent NH2- and carboxyl-terminal (N/C) inter-
action (1). The competitive relationship between AR FXXLF
and p160 coactivator LXXLLmotif binding to AF2 exerts a reg-
ulatory effect on p160 coactivator-induced AF2 activity that
favors transactivation from the AR NH2-terminal AF1 region
(2, 3). These findings, together with the greater ARAF2 binding
affinity for the AR FXXLF than coactivator LXXLL motifs (4),
suggest that AF1 in theARNH2-terminal region is the principal
AR activation domain.
Although regulation of steroid receptors through the AF2
site is relatively well described, the molecular mechanisms by
which coregulatory proteins mediate AR AF1 activity are not
understood. One recently described AR coregulator that inter-
acts with the AR NH2-terminal region, modulates the AR N/C
interaction, and increasesAR transcriptional activity is themel-
anoma antigen gene protein-A11 (MAGE-11).MAGE-11 binds
the AR NH2-terminal FXXLF motif and interacts directly with
p160 coactivators to increaseAR transcriptional activity (Fig. 1)
(5, 6). The interaction between AR and MAGE-11 is mediated
by aMAGE-11 F-box and modulated by epidermal growth fac-
tor (EGF)-induced phosphorylation of Thr-360 within the
F-box and monoubiquitinylation at lysine residues outside the
F-box (6, 7).
The functional importance of MAGE-11 as an AR coregula-
tor is supported by its regulated expression in normal human
reproductive physiology and deregulated expression in can-
cer. MAGE-11 levels increase by 50-fold in the epithelium
of the normal cycling human endometrium during the win-
dow of implantation (8) and to a similar extent in the CWR22
human prostate cancer xenograft during castration-recur-
rent growth. MAGE-11 levels were increased up to 1000-
fold in a subset of patients with castration-recurrent prostate
cancer (9). Increased expression of MAGE-11 provides a
mechanism to enhance AR signaling and is consistent with
the functional importance of AR during prostate cancer
progression.
The ability of MAGE-11 to increase the constitutive activity
of AR-(1–660), an NH2-terminal and DNA binding fragment,
when MAGE-11 itself lacks inherent transcriptional activity,
provided support for the idea that MAGE-11 functions as an
* This work was supported, in whole or in part, by National Institutes of Health
Cooperative Agreement U54-HD35041 from the Eunice Kennedy Shriver
NICHD (Specialized Cooperative Centers Program in Reproduction and
Infertility Research), Grant HD16910 from NICHD (USPHS), and by P01-
CA77739 from the NCI. This work was also supported by Department of
Defense PC073586 Fellowship Award.
1 Present address: Janelia Farm Research Campus, Howard Hughes Medical
Institute, Ashburn, VA 20147.
2 To whom correspondence should be addressed: Laboratories for Reproduc-
tive Biology, CB7500, University of North Carolina, Chapel Hill, NC 27599-
7500. Tel.: 919-966-5168; Fax: 919-966-2203; E-mail: emw@med.unc.edu.
3 The abbreviations used are: AR, androgen receptor; EGF, epidermal growth
factor; PSA-Enh-Luc, prostate-specific antigen enhancer luciferase; DHT,
dihydrotestosterone; siRNA, small inhibitory RNA; IP, immunoprecipita-
tion; GST, glutathione S-transferase; MAPK, mitogen-activated protein
kinase; ChIP, chromatin immunoprecipitation; CBP, cAMP-response ele-
ment-binding protein-binding protein; WT, wild type; N/C, NH2- and
carboxyl-terminal.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 285, NO. 28, pp. 21824 –21836, July 9, 2010
© 2010 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A.
21824 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 28 • JULY 9, 2010
AR coregulator through direct interactions with coactivators.
Based on sequence similarity between MAGE-11 and the ade-
novirus early protein E1A, an oncogenic protein that interacts
strongly with p300, we investigated the possible interaction
betweenMAGE-11 and p300, a ubiquitous transcriptional reg-
ulator and potent acetyltransferase (Fig. 1). p300 activates gene
transcription by acetylating histones and transcription factors
and as a coactivator of promoter-specific nuclear receptors
(10). Studies described here address the mechanisms underly-
ing the MAGE-11-dependent increase in AR transcriptional
activity arising from AR NH2-terminal AF1.
EXPERIMENTAL PROCEDURES
Expression Plasmids and Reporter Vectors—pCMV-hAR
(11), pCMV-AR-(1–660) (12), VP-AR and VP-AR-(1–660)
with wild-type sequence, L26A,F27A (LFAA) and 9–28
mutants (1, 13), pSG5-MAGE-11 (pSG5-MAGE), VP-MAGE-
11-(2–429) (VP-MAGE), and pCMV-FLAG-MAGE-11-(2–
429) (FLAG-MAGE) (5), pSG5-HA-MAGE-(112–429) and
pCMV-FLAG-ubiquitin (FLAG-Ub) (7), wild-type and F-box
mutants of pSG5-HA-MAGE fragments and pSG5-HA-
MAGE-(112–429) (6), pSG5-transcriptional intermediary
factor 2 (TIF2) (14), and pCMV-FLAG-TIF2 (6) expression
plasmids were described. Reporter vectors included prostate-
specific enhancer-luciferase (PSA-Enh-Luc) that contains the
3935 to 4326 upstream enhancer region of the PSA gene
cloned upstream of an E4 TATA box in pGL3 basic (15) and
5GAL4Luc3 that contains five copies of the GAL4 upstream
enhancer element (16, 17). pCMV, pSG5, VP16 activation
domain, and GAL-DNA binding domain expression vectors
contain the SV40 origin of replication for plasmid amplification
in SV40-transformed simian COS cells.
pSG5-HA-p300 was prepared by blunt-end cloning a NotI/
HindIII fragment of CMVb-NHAp300 (provided by Dr. David
Livingston, Dana-Farber Cancer Institute) into the BamHI
site of pSG5. pSG5-HA-p300-D1399Y, I97A,F98A, and
I188A,F189A were created by QuikChange site-directed
mutagenesis (Stratagene) using pSG5-HA-p300 as template.
GAL-MAGE fragments were created by PCR mutagenesis.
pCMV-FLAG-p300 fragments were created by PCR amplifying
pSG5-HA-p300, digesting with EcoRI/ClaI (FLAG-p300-(2–
300) and -(2–357)) or HindIII/ClaI (FLAG-p300-(270–357),
-(300–670), -(357–670), and -(450–670)), and ligating into the
same sites of pCMV-FLAG. Additional FLAG-p300 fragments
were created by ligating EcoRI/XbaI fragments of GAL-p300-
(2–270) and -(2–300) and a SalI/XbaI fragment of GAL-p300-
(230–670) into the same sites of pCMV-FLAG. GST-p300-(2–
357) was created by inserting the EcoRI/SalI fragment from
FLAG-p300-(2–357) into the same sites of pGEX-4T-1.
GAL-p300-(2–300), -(230–670), -(501–999), -(1000–1600),
-(1601–1900), and -(1901–2414) were created by PCR amplify-
ing the indicated regions of pSG5-HA-p300 and cloning SalI/
ClaI-digested fragments into the same sites of GAL0. GAL-
p300-(2–357) was created by digesting FLAG-p300-(2–357)
with EcoRI/XbaI and ligating the fragment into the same sites
of GAL0. GAL-p300-(2–300)-L36A,F37A was created using
QuikChange site-directed mutagenesis and GAL-p300-(2–
300) as template. GAL-p300-(230–670) was created by PCR
amplifying pSG5-HA-p300, digesting with SalI/ClaI, and
inserting the fragment into GAL0. Other GAL-p300 fragments
were created by PCR amplifying GAL-p300-(2–300), digesting
the fragments with SalI/ClaI (GAL-p300-(2–270), -(2–230),
-(2–180), -(90–300), and -(90–270)) or EcoRI/ClaI (GAL-
p300-(48–300)), and ligating into the same sites of GAL0. All
PCR-amplified regions were verified by DNA sequencing.
Expression Studies—Monkey kidneyCV1 cells (4 105/6-cm
dish) were transfected using calcium phosphate DNA precipi-
tation (3) with 0.1 g of pCMV-AR and the indicated amounts
of wild-type and mutant pSG5-MAGE, pSG5-TIF2, and pSG5-
HA-p300 and 3 or 5 g PSA-Enh-Luc. After transfection and
24 h later, cells were placed in serum-free, phenol red-free
media in the absence and presence of 1 nM dihydrotestosterone
(DHT). The next day, the medium was replaced, and 24 h later
cells were extracted in 0.25ml of luciferase lysis buffer contain-
ing 1% Triton X-100, 2 mM EDTA, and 25 mM Tris phosphate,
pH 7.8. Luciferase activity was measured using an automated
Lumistar Galaxy multiwell plate luminometer (BMG Labtech).
Luciferase activity shown is representative of at least three inde-
pendent experiments, and the graphs show the mean  S.E.
Two-hybrid transfection assays were performed in HeLa
human epithelial cervical carcinoma cells using FuGENE 6
(RocheApplied Science) by plating 5 104 cells/well in 12-well
plates (4). Cells were transfected with 0.1 g/well 5GAL4
Luc3 and 0.05 g GAL-p300 fragments with 0.05 g of pVP16
empty vector or VP-MAGE. The day after transfection, cells
were transferred to serum-free medium and incubated over-
night at 37 °C before luciferase activity was measured.
SiRNA was transfected into COS cells (4  105/well in 6-
well plates) using Lipofectamine 2000 (Invitrogen) in the
absence of antibiotics with 1g of pSG5-MAGE, 1g of pSG5-
TIF2, or 2 g of pSG5-HA-p300 in the absence and presence of
5 nM MAGE-11 siRNA-2 GCACUGAUCCUGCAUGCUAUU,
FIGURE 1. Functional interaction between AR, MAGE-11, p300, and TIF2.
AR transcriptional activity is increased through interactions with MAGE-11,
p300, and TIF2. AR contains a centrally located DNA binding domain (DBD)
and activation function 1 (AF1) region in the NH2-terminal region. AR NH2-
terminal FXXLF motif 23FQNLF27 interacts with the AR activation domain 2
(AF2) region of the ligand binding domain (LBD) in the androgen-dependent
AR N/C interaction and with the MAGE-11 F-box residues 329 –369 (6).
MAGE-11 contains MXXIF motif 185MDAIF189 that interacts with the NH2-ter-
minal region of p300 and FXXIF motif 260FPEIF264 that interacts with TIF2 (6). A
p300 NH2-terminal FXXLF motif
33FGSLF37 interacts with TIF2, and TIF2 LXXLL
motif 745LRYLL749 interacts with AF2 in the AR ligand binding domain. These
motif-driven interactions occur in a temporal and/or competitive manner and
are influenced by the cell cycle and post-translation modification that
includes phosphorylation, ubiquitinylation, and acetylation. The acetylase
activity of p300 is required for MAGE-11 and TIF2 to increase AR transcrip-
tional activity.
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MAGE-11 siRNA-3 CAACUGCUCUUUGGCAUUGUU, 5 nM
TIF2 siRNA-3 GAUCAGAAGUGACUAUUAA, 10 nM p300
siRNA-1 GAAAUUAGGUUACACAACA, p300 siRNA-2
GGACUACCCUAUCAAGUAA, p300 siRNA-3 GAACAUG-
GCUCCACAACCA, p300 siRNA-4 GGCAGUAUGUCGA-
UGAUAU, and nonspecific siRNA-5 UGGUUUACAUGUC-
GACUAA (Dharmacon RNA Technologies). The day after
transfection, cells were harvested or transferred to serum-free
medium and harvested 24 h later for immunoblot analysis. For
siRNA experiments in HeLa cells, cells were plated in antibiotic-
free medium and transfected using Lipofectamine 2000.
Immunoblotting—Relative expression levels of wild-type and
mutant vectors were determined by transfecting COS cells (2
106/10-cm dish) with 4–8 g of DNA using DEAE-dextran (4,
18). The next day, cells were transferred to serum-free media
with orwithout 1MMG132proteosome inhibitor (Sigma) and
24 h later harvested in phosphate-buffered saline. Cell pellets
were extracted in 0.1 to 0.2 ml of immunoblot lysis buffer con-
taining 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS,
0.15 M NaCl, 2 mM EDTA, 0.05 mM NaF, 2 mM sodium vana-
date, 50mMTris-HCl, pH 7.5, with 1mM phenylmethylsulfonyl
fluoride, 1 mM dithiothreitol, and complete protease inhibitor
mixture (Roche Applied Science). Cell extracts were analyzed
on 8, 10, or 12% acrylamide gels containing SDS. Proteins were
transferred overnight to nitrocellulose membranes at 4 °C, and
transblots were probed with the following antibodies: rabbit
anti-humanAR-32 immunoglobulin G (0.4g/ml); rabbit anti-
GAL4-DNA binding domain (Santa Cruz Biotechnology
sc-577, 1:500 dilution); rabbit polyclonal FLAG-MAGE anti-
body-1 (0.5 g/ml) raised against purified baculovirus-ex-
pressed FLAG-tagged human MAGE-11; affinity-purified rab-
bit polyclonal human p300 (C-20) antibody (Santa Cruz
Biotechnology sc-585, 1:75–200 dilution); mouse anti--actin
(Abcam, 1:5000 dilution); mouse anti-TIF2 (BD Transduction
Laboratories, 1:100–250 dilution); rabbit anti-MAGE-11 pep-
tide antibodies MAGE-Ab-13–26, 59–79, and 94–108 immu-
noglobulin G (4–10 g/ml) (8); mouse anti-FLAG M2 mono-
clonal antibody (Sigma F3165,1:500–2000 dilution); rabbit
polyclonal acetylated lysine antibody (Cell Signaling 9441,
1:1000 dilution); rabbit anti-hemagglutinin tag (Abcam ab9110,
1:2000 dilution); and rabbit anti-VP16 activation domain (Abcam
ab4809, 1:2000 dilution). Gels were calibrated using EZ-Run
prestained Rec protein ladder (Fisher Bioreagents), and immuno-
reactivity was detected by chemiluminescence (Super-
SignalWest Dura Extended Duration Substrate, Pierce).
Immunoprecipitation was performed by transfecting COS
cells as above using two 10-cm plates/group. For protein acety-
lation assays, COS cells were treated for 1 h prior to harvest
with histone deacetylase inhibitor 5 mM nicotinamide with and
without 5 mM sodium butyrate. Cell lysates were prepared in
0.25 volume of immunoprecipitation (IP) lysis buffer contain-
ing 1% Triton X-100, 0.5% deoxycholate, 0.15 M NaCl, 0.05 M
NaF, 1 mM EDTA, and 50 mM Tris, pH 7.6, with 1 mM phenyl-
methylsulfonyl fluoride, 1mMdithiothreitol, complete protease
inhibitor mixture (Roche Applied Science) with or without his-
tone deacetylase inhibitors 5 mM nicotinamide and 5 mM
sodium butyrate. Lysates were diluted 4-fold with IP buffer
lacking deoxycholate and precleared for 1 h at 4 °C with 0.1 ml
of Sepharose CL-4B (Sigma). To coimmunoprecipitate endog-
enous p300 with FLAG-MAGE, human embryonic kidney 293
(HEK293) cells maintained in minimal essential medium con-
taining 2 mM L-glutamine, 10% fetal bovine serum, and penicil-
lin and streptomycin (15  106 cells/10-cm dish, seven dishes/
group) were transfected using DEAE-dextran. HEK293 cell
extracts were prepared in 0.5 volume of IP lysis buffer and
diluted with an equal volume of IP buffer without deoxycholate
prior to preclearing for 10 min at 4 °C with 50 l of Sepharose
CL-4B. COS andHEK293 cell extracts were transferred to 15l
of anti-FLAGM2-agarose (Sigma) for 2 h or overnight incuba-
tion at 4 °C. The next day, samples were pelleted and washed
with IP lysis buffer without deoxycholate, resuspended in 0.05
ml of 2 SDS sample buffer containing 3.3% SDS, 10% 2-mer-
captoethanol, 10% glycerol, and 0.12 M Tris-HCl, pH 6.8, incu-
bated for 5 min at 90 °C, and analyzed on immunoblots as
described above.
In Vitro Binding Assays—Glutathione S-transferase (GST)
interaction assays were performed using pGEX-4T-1 empty
vector and pGEX-4T-1-p300-(2–357) (GST-p300-(2–357)).
35S-MAGE-11 was prepared using pSG5-MAGE and the TNT
T7 Quick-coupled transcription-translation system (Promega)
(1, 6, 19). GST fusion proteins were expressed in BL-21 DE3
Escherichia coli with 1 mM isopropyl 1-thio--D-galactopyr-
anoside for 3 h at 37 °C. Cell pellets were resuspended in GST
binding buffer containing 0.5% Nonidet P-40, 1 mM EDTA, 0.1
M NaCl, 10% glycerol, 20 g/ml bovine serum albumin, and 20
mM Tris-HCl, pH 8.0, with 1 mM dithiothreitol and complete
protease inhibitor mixture (Roche Applied Science). Glutathi-
one-Sepharose 4B (GE Healthcare) was incubated for 1.5 h at
4 °C with GST-0 and GST-p300-(2–357) cell lysates after soni-
cation. Beads were washed with GST buffer, combined with 25
Ci of 35S-MAGE-11, and incubated overnight at 4 °C. The
resin was washed, eluted with SDS, and analyzed on an 8–16%
gradient minigel containing SDS (Invitrogen). The dried gel
was exposed to x-ray film for 48 h.
Chromatin Immunoprecipitation (ChIP)—ChIP assays were
performed using LAPC-4 human prostate cancer cells (10 
106 cells/10-cm dish, three dishes/group) plated in RPMI 1640
medium (Invitrogen) supplemented with 10% charcoal-
stripped fetal bovine serum (Atlanta Biologicals), 2 mM L-gluta-
mine, penicillin, and streptomycin. Cells were treated 72 h after
plating for 24 h at 37 °C with and without 10 nM DHT and
cross-linked using 1% formaldehyde for 10 min at room tem-
perature followed by 0.125 M glycine. After 10 min at room
temperature, cells were harvested and washed with phosphate-
buffered saline and lysed in 1.2ml of 1%SDS, 5mMEDTA, 1mM
phenylmethylsulfonyl fluoride, and 50 mM Tris-HCl, pH 8.1,
with and without 10 nM DHT. After a 10-min incubation at
4 °C, cells were sonicated 12 times for 5 s at 50%power to obtain
100–1000-bp DNA fragments. Lysates were clarified by centri-
fugation and 0.45 ml diluted 10-fold with 1% Triton X-100, 2
mM EDTA, 0.15 M NaCl2, 1 mM phenylmethylsulfonyl fluoride,
and 20 mM Tris-HCl, pH 8.1, with and without DHT. Samples
were precleared for 4 h at 4 °C with 20 l of protein-A-agarose
(Sigma) and pelleted. Immunoprecipitation was performed
overnight at 4 °C by adding 10 g of the following antibodies to
0.75-ml sample: rabbit anti-AR H-280 (Santa Cruz Biotechnol-
Transactivation Synergy of AR, MAGE-11, and p300
21826 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 28 • JULY 9, 2010
ogy sc-13062), rabbit anti-p300 C-20 (Santa Cruz Biotechnol-
ogy sc-585), normal rabbit IgG (Santa Cruz Biotechnology
sc-2077), rabbit polyclonal MAGE antibody-1 raised against
baculovirus-expressed FLAG-tagged human MAGE-11, and
MAGE-11 rabbit anti-peptide antibody MAGE-Ab-94–108
IgG (8). PCR was performed in 15-l reactions using Taq
polymerase (Qiagen) and 0.6 l of 10 M PSA upstream
enhancer primers 5-GGGACAACTTGCAAACCTG-3 and
5-GTATCTGTGTGTCTTCTGAGC-3 at 95 °C for 5 min, 37
cycles of 95 °C for 30 s, 57 °C for 30 s, 72 °C for 20 s, and 72 °C for
10min to amplify a 285-bp fragment from the4234 to3950
5-flanking region.
RESULTS
MAGE-11 Increases p300-dependent AR Transcriptional
Activity—To determine whether MAGE-11 increases AR tran-
scriptional activity through mechanisms that involve p300, AR
was expressed in the absence and presence of MAGE-11 and
p300 with a PSA-Enh-Luc reporter vector that contains an
androgen-responsive enhancer (15). Androgen-dependent AR
activity increased to a greater extent with the coexpression
of MAGE-11 than with p300. Transcriptional activity
increased further when MAGE-11 and p300 were coex-
pressed (Fig. 2A) and was greatest when TIF2 was also coex-
pressed (Fig. 2, A and B).
The effects of MAGE-11 and p300 on AR transcriptional
activity from the NH2-terminal AF1 region were evaluated
using AR-(1–660), an AR NH2-terminal and DNA binding
domain fragment. MAGE-11 or p300 increased AR-(1–660)
activity andwere synergistic when expressed together (Fig. 2C).
As seen with full-length AR (Fig. 2B), TIF2 did not increase
AR-(1–660) activity except when expressed with p300 or
MAGE-11 (Fig. 2D).
Dependence on MAGE-11 for the TIF2-induced increase in
AR activity could be explained by previous findings that
MAGE-11 interacts with TIF2 (6) and that binding of
MAGE-11 to the AR FXXLF motif overcomes an inhibitory
effect of theARN/C interaction onTIF2 binding toAF2 (Fig. 1)
(3). The synergistic effects ofMAGE-11 and p300 on transcrip-
tional activity mediated by the AR NH2-terminal region sug-
gested that MAGE-11 may interact directly with p300.
MAGE-11 Interacts with the NH2-terminal Region of p300—
Mammalian two-hybrid assays were performed to investigate
an interaction between MAGE-11 and p300. VP-MAGE was
expressed with a GAL4-luciferase reporter and GAL4-DNA
binding domain fusion proteins containing different regions
of p300 (Fig. 3A). MAGE-11 interacted with the p300-(2–
300) NH2-terminal region to a greater extent than with
p300-(230–670) (Fig. 3B). MAGE-11 did not interact with
the p300-(501–999) Kix domain, 1000–1600-residue Bromo
domain, PHD and histone acetyltransferase domains (20–
22), or the 1601–1900-residue ZZ and Taz2 domains (23).
Constitutive activity of the carboxyl-terminal fragment
p300-(1901–2414) that included an IBiD domain (24) was
only slightly increased by MAGE-11.
To investigate the influence of MAGE-11 on transcriptional
activity from the p300 NH2-terminal region, additional GAL-
p300 fragments were expressed with a MAGE-(112–429) car-
boxyl-terminal fragment in transient transfection assays using
theGAL-luciferase reporter (Fig. 3C). Similar to the two-hybrid
interaction results (Fig. 3B), MAGE-(112–429) increased tran-
scriptional activity from GAL-p300-(2–357), -(2–300), -(2–
270), and -(230–670) comparedwith other p300NH2-terminal
fragments (Fig. 3C). Overall activity decreased with deletion of
the p300 NH2-terminal region in GAL-p300-(48–300) or with
mutations in a p300 NH2-terminal FXXLF motif 33FGSLF37
in GAL-p300-(2–300)-L36A,F37A. The results suggest that
MAGE-11 interacts with and increases transcriptional activity
associated with the p300 NH2-terminal region.
p300 Interacts with the Carboxyl-terminal Region of MAGE-
11—Based on the ability of MAGE-(112–429) to increase
GAL-p300-(2–300) activity (Fig. 3C), we determined which
MAGE-11 regions were required for this effect. Coexpression
of full-length MAGE-11 caused less of an increase in GAL-
p300-(2–300) activity than MAGE-(112–429), and there was
no increase with MAGE-11 fragments that did not include
F-box amino acid residues 329–369 shown previously to inter-
act with the AR FXXLF motif (Fig. 4, A and B) (6).
A requirement for the MAGE-11 F-box to increase GAL-
p300-(2–300) transcriptional activity was supported by the loss
in activity associated with a series of single amino acid
MAGE-11 F-box mutants (Fig. 4C) that also decreased
MAGE-11 binding to the AR FXXLF motif (6). Mutation of
MAPK site Ser-174 blocked the MAGE-(112–429)-dependent
increase in GAL-p300-(2–300) activity and was recovered with
FIGURE 2. MAGE-11 and p300 increase AR transcriptional activity. CV1
cells were transfected with the following: A, 5 g of PSA-Enh-Luc and 0.1 g of
pCMV-AR, 1.5 g of pSG5-MAGE, and 1.5 g of pSG5-HA-p300 alone and
together; B, 0.1 g of pCMV-AR in the absence and presence of 1 g of pSG5-
MAGE, 2 g of pSG5-TIF2, and 2 g of pSG5-HA-p300; C, 10 ng of pCMV5
empty vector (p5) or pCMV-AR-(1– 660) with and without 0.5 g of pSG5-
MAGE and 2 g of pSG5-HA-p300; and D, 10 ng of pCMV-AR-(1– 660) with and
without 0.5 g of pSG5-MAGE, 2 g of pSG5-TIF2, and 2 g of pSG5-HA-p300.
Cells were incubated in the absence and presence of 1 nM DHT.
Transactivation Synergy of AR, MAGE-11, and p300
JULY 9, 2010 • VOLUME 285 • NUMBER 28 JOURNAL OF BIOLOGICAL CHEMISTRY 21827
the MAGE-(112–429)-S174D phosphomimetic (Fig. 4D). A
predicted MAGE-11 phosphorylation site at Ser-298 when
mutated to alanine decreased the MAGE-(112–429)-de-
pendent increase in GAL-p300-(2–300) activity but was only
partially restored with the S298D phosphomimetic.
A direct interaction between MAGE-11 and the p300 NH2-
terminal region was supported by in vitro binding studies in
which GST-p300-(2–357) interacted with 35S-labeled MAGE-
11 (Fig. 4E). In addition, endogenous p300 coimmunoprecipi-
tated with FLAG-MAGE in HEK293 cells (Fig. 4F). However,
the low levels and cell cycle-dependent expression of endoge-
nousMAGE-11 (see Fig. 11A) hindered further analysis of these
protein-protein interactions.
The results suggest that the carboxyl-terminal region of
MAGE-11 interacts with the NH2-terminal region of p300
and increases p300 transcriptional activity through mecha-
nisms that depend on the MAGE-11 F-box and MAPK phos-
phorylation. The apparent inhibitory effect of the MAGE-11
NH2-terminal region onGAL-p300
transcriptional activity (Fig. 4B) sug-
gested the presence of an auto-reg-
ulatory mechanism.
MAGE-11MXXIFMotif Interacts
with p300—To further characterize
the MAGE-11 interaction with
p300, transcriptional activation of
GAL-luciferase was measured after
expressing full-length p300 with a
series of GAL-MAGE fragments
(Fig. 5A). GAL-MAGE and GAL-
MAGE-(112–429) were activated
to only a limited extent by p300
(Fig. 5B). In contrast, p300 strongly
activated GAL-MAGE-(112–205),
-(140–205), -(161–205), -(85–205),
and -(85–152) but not -(100–152)
(Fig. 5B).
Within the MAGE-(85–205) re-
gion that was activated by p300 are
two (M/I)XXIF motifs, 94ITQIF98
and 185MDAIF189 (Fig. 5A). The
functional importance of the
185MXXIF189 motif was suggested
by the decrease in GAL-MAGE-
(85–205)-I188A,F189A activity in
the presence of p300 and by the
lower activity of GAL-MAGE-
(140–205)-I188A,F189A that lacked
the 94IXXIF98 motif (Fig. 5C). Dis-
ruption of the 94IXXIF98 motif in
GAL-MAGE-(85–205)-I97A,F98A,
inwhich the 185MXXIF189motif was
intact, had no effect on p300-depen-
dent activity. However, activity
decreased with the GAL-MAGE-
(85–152)-I97A,F98A 94IXXIF98motif
mutant that lacked the 185MXXIF189
motif (Fig. 5C).
The MAGE-11 185MXXIF189 motif was also required for
p300 to increase AR transcriptional activity. Mutations in
either the MXXIF or IXXIF motif in full-length MAGE-11 did
not significantly decrease AR transcriptional activity when
assayed using the PSA-Enh-Luc reporter without coexpression
of p300 or TIF2 (Fig. 5D). However, mutations in the
185MXXIF189motifminimized or eliminated theMAGE-11-de-
pendent increase inAR transcriptional activity with the expres-
sion of p300 and/or TIF2. AR activity was similar to wild-type
with mutations in the MAGE-11 94IXXIF98 motif.
The results suggest that MAGE-11MXXIF motif sequence
185MDAIF189 is a primary interaction site for p300 (Fig. 1),
and the IXXIF motif sequence 94ITQIF98 is a secondary
interaction site. The inability of p300 to increase GAL-
MAGE or GAL-MAGE-(112–429) activity while smaller
fragments were strongly activated by p300 (Fig. 5B) sug-
gested that the MAGE-11 carboxyl-terminal region has an
inhibitory effect.
FIGURE 3. MAGE-11 interacts with the p300 NH2-terminal region. A, schematic diagram of p300 interaction
domains and fragments analyzed for interaction with MAGE-11. B, indicated GAL-p300 vectors (0.05 g) were
transfected into HeLa cells with 0.1 g of 5GAL4Luc3 and 0.05 g of pVP16 empty vector () or VP-MAGE.
Lower panel, COS cells were transfected with 8 g of GAL-p300 vectors and incubated with 1 M MG132 for 24 h
prior to harvest. Cell extracts (50 g of protein/lane) were analyzed on immunoblots using anti-GAL4-DNA
binding domain antibody. C, indicated GAL-p300 vectors (0.05 g) were transfected into HeLa cells with 0.1 g
of 5GAL4Luc3 and 0.1 g of pSG5 empty vector () or pSG5-HA-MAGE-(112– 429). Lower panel, COS cells
were transfected with 5 g of GAL-p300 vectors and incubated with 1 M MG132 for 24 h and 1 h prior to
harvest. Cell extracts (60 g of protein/lane) were analyzed on the transblot using GAL4-DNA binding domain
antibody. HAT, histone acetyltransferase.
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Functional Requirement for AR and p300 NH2-terminal
FXXLF Motifs—p300 has an NH2-terminal FXXLF motif
sequence 33FGSLF37 in a similar relative position to the AR
FXXLF motif (Fig. 6A). Evidence that the p300 FXXLF motif
was required to enhance GAL-p300-(2–300) activity (Fig. 3C),
in addition to the close proximity of flanking charged residues
(Fig. 6A), suggested that the p300 NH2-terminal FXXLF motif
was functionally important. Because previous studies demon-
strated AR activation of androgen-responsive enhancer/pro-
moters depends on the AR FXXLF motif (25), we investigated
the requirement for NH2-terminal FXXLF motifs in the AR
interaction with p300.
Mammalian two-hybrid assays using the GAL-luciferase
reporter showed that the AR FXXLF motif was required for an
interaction between VP-AR-(1–660) and GAL-p300-(2–300).
AR interaction with p300 was eliminated with VP-AR-(1–
660)-L26A,F27A in which the AR FXXLF motif was mutated
(Fig. 6B). Deletion of the p300 FXXLF motif in GAL-p300-
(48–300) or GAL-p300-(90–300) decreased overall activity
and the requirement for the AR FXXLF motif but did not
eliminate the interaction with AR. A weak androgen-depen-
dent interaction between full-length VP-AR and GAL-p300-
(2–300) was inhibited with VP-AR-L26A,F27A and
VP-AR9–28, in which the AR FXXLF motif was mutated or
deleted (Fig. 6C). Deletion of the p300 FXXLF motif
increased the androgen-dependent interaction between
GAL-p300-(48–300) and VP-AR and was eliminated with
VP-AR-L26A,F27A or VP-AR9–28.
To better understand the functional requirement for the
p300 NH2-terminal FXXLF motif, GAL-p300-(2–300) was
FIGURE 4. Transcriptional effects of MAGE-11 interaction with p300. A, schematic diagram of MAGE-11 showing nuclear localization signal (NLS) residues
18 –22; phosphorylation sites Ser-174 (6), Ser-208, and Thr-360; ubiquitinylation (Ub) sites Lys-240 and 245 (7); F-box residues 329 –369 (6); and MAGE-11
fragments. MHD, MAGE homology domain. For the two-hybrid assays, HeLa cells were transfected with 0.1 g of 5GAL4Luc3 and the following: B, 0.05 g of
GAL-p300-(2–300) and 0.1 g of pSG5 empty vector () or pSG5-HA-MAGE-(2– 429), -(112– 429), -(112–362), -(112–307), -(112–298), or -(112–276); C, 25 ng of
GAL-p300-(2–300) and 0.1 g of pSG5 () or wild-type (WT) pSG5-HA-(112– 429) or indicated F-box mutant; and D, 0.05 g of GAL-p300-(2–300) and 0.1 g
of pSG5 () or WT pSG5-HA-MAGE-(112– 429) or S174A, S174D, S298A, or S298D mutant. B–D, lower panels, COS cells were transfected with 4 g of pSG5 ()
or the indicated pSG5-HA-MAGE vectors. Cells expressing GAL fusion proteins were treated with 1 M MG132 for 24 h and 1 h prior to harvest. Transblots of cell
extracts for GAL4 fusion proteins (60 g of protein/lane) and HA-MAGE (30 g of protein/lane) were probed using GAL or hemagglutinin (HA) antibodies. E, in
vitro interaction between MAGE-11 and p300 was performed using GST-p300-(2–357) and 35S-labeled MAGE-11. The input represents 10% of the total reaction.
F, endogenous p300 was immunoprecipitated from HEK293 cells transfected with 3 g of FLAG empty vector () (lane 1) or FLAG-MAGE (lane 2). Cells were
treated with 0.1 g/ml EGF and 1 M MG132 24 h prior to harvest and incubated for 2 h with FLAG affinity resin. Cell extracts (0.15 mg of protein/lane) and
immunoprecipitates were analyzed on transblots probed using FLAG and p300 antibodies.
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expressed with TIF2 in a transient transcription assay using the
GAL-luciferase reporter. GAL-p300-(2–300) was strongly acti-
vated byTIF2 (Fig. 6D) in a p300 FXXLFmotif-dependentman-
ner. TIF2-dependent GAL-p300-(2–300) activity decreased
with GAL-p300-(48–300) in which the p300 FXXLF motif was
deleted and with GAL-p300-(2–300)-L36A,F37A in which the
p300 FXXLF motif was mutated.
A contribution ofMAGE-11 to theTIF2-dependent increase in
GAL-p300-(2–300) activity was further suggested through the
use of siRNAs to lower protein levels. MAGE-11 siRNA-2
reduced MAGE-11 levels (Fig. 7A, top panel) and inhibited
inherent GAL-p300-(2–300) transcriptional activity but did
not eliminate the increase with TIF2 (Fig. 7B). MAGE-11
siRNA-3 was less effective in decreasing MAGE-11 levels
(Fig. 7A), and the TIF2-induced increase in GAL-p300-(2–
300) activity was similar to that seen in the absence and
presence of nonspecific siRNA. TIF2 siRNA-3 decreased
both TIF2 expression (Fig. 7A, bottom panel) and the TIF2-
FIGURE 5. Identification of MAGE-11 185MDAIF189 and 94ITQIF98 interaction sites for p300. A, schematic diagram of MAGE-11 showing 94ITQIF98 and
185MDAIF189 interaction motifs for p300, 260FPEIF264 interaction motif for TIF2, MAGE-11 F-box (residues 329 –369) interaction site for the AR FXXLF motif (6),
nuclear localization signal (NLS), Ser-174 and Thr-360 phosphorylation sites, Lys-240 and -245 ubiquitinylation sites, and MAGE-11 fragments to test the
interaction with p300. Inset, GAL-MAGE fragments were expressed in COS cells transfected with 6 g of DNA and incubated with 1 M MG132 for 24 h and again
1 h prior to harvest. The transblot of cell extracts (100 g/lane) was probed using GAL4-DNA binding domain antibody. MHD, MAGE homology domain. B, HeLa
cells were transfected with 0.1 g of 5GAL4Luc, 0.05 g of GAL-MAGE fragments, and 0.15 g of pSG5 empty vector () or pSG5-HA-p300. C, HeLa cells were
transfected with 0.1 g of 5GAL4Luc3, 0.05 g of GAL-MAGE fragments, and 0.1 g of pSG5 () or pSG5-HA-p300. Lower panel, GAL-MAGE fragments were
expressed in COS cells transfected with 5 g of DNA and incubated with 1 M MG132 for 24 h prior to harvest. The transblot of cell extracts (80 g/lane) was
probed using GAL4-DNA binding domain antibody. D, dependence of AR transcriptional activity on p300 and MAGE-11 185MDAIF189 motif was performed by
transfecting CV1 cells with 0.1 g of pCMV-AR and 3 g of PSA-Enh-Luc in the absence and presence of 1 g of pSG5-MAGE, 2 g of pSG5-TIF2, and 2 g of
pSG5-HA-p300. Cells were incubated for 48 h in the absence and presence of 1 nM DHT. Inset, expression was verified in COS cells transfected with 3 g of pSG5
empty vector DNA () (lane 1), WT pSG5-MAGE (lane 2), and I188A,F189A and I97A,F98A mutants (lanes 3 and 4). Cell extracts (10 g/lane) were probed using
FLAG-MAGE antibody-1 (0.5 g/ml).
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dependent increase in GAL-p300-(2–300) activity (Fig. 7B).
The results suggest that the AR interaction with p300 is
influenced by NH2-terminal FXXLF motifs present in both
proteins and that the p300 FXXLF
motif facilitates transcriptional
activation by TIF2 (Fig. 1).
Multiple Functions of the AR
FXXLF Motif—Previous studies have
demonstrated the requirement for
the androgen-dependent AR N/C
interaction between the AR FXXLF
motif and AF2 in AR activation of
androgen-responsive enhancer/
promoters (1, 25). These findings,
together with the requirement for
the AR FXXLF motif in functional
interactions involving MAGE-11
and p300, provided evidence that
the AR N/C interaction influences
AR transactivation involving p300.
To investigate this further, we
determined the effect of MAGE-11
and p300 using an experimental
paradigm that depended on the
androgen-dependent ARN/C inter-
action.AR-(507–919) is anARDNA
and ligand binding domain frag-
ment that lacks the NH2-terminal
region and retains high affinity
androgen binding (26). AR-(507–
919) alone did not activate a PSA-
Enh-Luc reporter in the presence of
DHT with or without coexpression
of MAGE-11 or p300 alone or
together (Fig. 8A). However, expres-
sion of AR-(507–919) with AR-(1–
503), an ARNH2-terminal fragment
that lacks the AR DNA and ligand binding domains, resulted in
androgen-dependent activity that was increased by expressing
MAGE-11 or p300 and was highest when all were expressed
together. An interaction between AR-(507–919) and AR-(1–503)
was required for transcriptional activation and depended on AR
FXXLF motif binding to AF2 in the ligand binding domain (1).
Dependence on theARN/C interaction for the increase in activity
byMAGE-11 and p300was shown by loss of AR-(507–919) activ-
ity expressed with AR FXXLF motif mutant AR-(1–503)-
L26A,F27Awith or withoutMAGE-11 or p300 alone or together.
The requirement for endogenous p300 in AR N/C interac-
tion-dependent AR transactivation was demonstrated further
using p300 siRNA. p300 siRNA-1, -3, and -4 each decreased
p300 levels (Fig. 8B) and decreased the androgen-dependent
activity of AR-(507–919) and AR-(1–503) coexpressed with
MAGE-11 in the presence of DHT (Fig. 8C). Specificity of
siRNA inhibition was indicated by wild-type activity associated
with nonspecific siRNA and p300 siRNA-2 that did not reduce
p300 levels.
To demonstrate further thatMAGE-11 functionally linksAR
and p300 through the AR FXXLF motif, GAL-AR-(16–36),
which contains only theARNH2-terminal FXXLFmotif region,
was expressed with wild-type or mutant MAGE-11 and p300
alone or together in the presence of a GAL-luciferase reporter.
FIGURE 6. Functional effects of AR and p300 NH2-terminal FXXLF motifs. A, AR NH2-terminal
23FQNLF27 and
p300 NH2-terminal
33FGSLF37 FXXLF motifs (red) are flanked by basic and acidic residues (blue). B, HeLa cells
were transfected with 0.1 g of 5GAL4Luc3 and 0.05 g of GAL0 empty vector () or GAL-p300-(2–300),
-(48 –300), or -(90 –300) and 0.1 g of VP16 empty vector () or WT VP-AR-(1– 660) or L26A,F27A (LFAA) mutant.
B and C insets, COS cells were transfected with 6 g of VP16 empty vector () and VP-AR-(1– 660) (B) or VP-AR
(C) with wild-type, L26A,L27A (LFAA) mutations, or 9 –28 deletion and treated 24 h later in serum-free
medium with 1 M MG132 for 24 h and again for 1 h prior to harvest. Transblots of cell extracts (60 g of
protein/lane) were probed using VP16 antibody. C, HeLa cells were transfected with 0.1 g/ml 5GAL4Luc3,
0.05 g of GAL0 empty vector (), GAL-p300-(2–300) or -(48 –300) with 0.1 g of VP16 empty vector () or
full-length AR fusion vectors VP-AR WT, L26A,F27A (LFAA), or 9 –28 mutant. Cells were incubated in the
absence and presence of 10 nM DHT. D, HeLa cells were transfected with 0.1 g of 5GAL4Luc3 and 0.05 g of
GAL-p300-(2–300), -(48 –300), and L26A,F27A (LFAA) with 0.1 g of pSG5 empty vector () or pSG5-TIF2.
FIGURE 7. Dependence of GAL-p300-(2–300) transcriptional activity on
MAGE-11 and TIF2. A, inhibition of MAGE-11 (upper panel) and TIF2 (lower panel)
expression by siRNA was performed by transfecting COS cells using Lipo-
fectamine 2000 with 1 g of pSG5 empty vector (lane 1), 1 g of pSG5-MAGE (top
panel), or pSG5-TIF2 (bottom panel) in the absence and presence of 5 nM MAGE-11
siRNA-2 or -3, TIF2 siRNA-3, and nonspecific (NS) siRNA-5. The next day cells were
harvested (TIF2) or transferred to fresh serum-free medium and harvested 24 h
later (MAGE-11). Cell extracts for MAGE-11 (10 g of protein/lane) and TIF2 (40 g
of protein/lane) were analyzed on transblots probed with MAGE-Ab-(94–108),
TIF2, and -actin antibodies. B, HeLa cells (105/well in 12-well plates) were trans-
fected using Lipofectamine 2000 with 0.1 g of 5GAL4Luc3 and 0.05 g of
GAL-p300-(2–300) in the absence and presence of 0.1 g of pSG5 empty vector
() or pSG5-TIF2 in the absence and presence of 5 nM nonspecific siRNA-5 (NS-5),
MAGE-11 siRNA-2 or -3, and TIF2 siRNA-3.
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NeitherMAGE-11 nor p300 alone increased GAL-AR-(16–36)
activity but together were strongly synergistic (Fig. 8D). Muta-
tions in theMAGE-11 185MXXIF189motif that was required for
MAGE-11 to interact with p300 (Fig. 5) reduced p300 activa-
tion of GAL-AR-(16–36), although there was only a slight
decrease with mutations in the MAGE-11 94IXXIF98 motif, in
agreement with the results in Fig. 5. Dependence of MAGE-11
and p300-induced GAL-AR-(16–36) activity on the AR FXXLF
motif interaction withMAGE-11 was demonstrated by loss of
transcriptional activity with the L358A and T360A
MAGE-11 F-box mutants and with the MAGE-11 ubiquiti-
nylation site mutant K240A,K245A, where each mutation
disrupted MAGE-11 binding to the AR FXXLF motif (6, 7).
Dependence on theARFXXLFmotif was shownby the absence of
GAL-AR-(16–36)-L26A,F27AFXXLFmotifmutantactivitywhen
expressed with MAGE-11 and p300.
GAL-AR-(16–36) activity in the
presence of MAGE-11 was also re-
duced when coexpressed with p300-
D1399Y (Fig. 8D), a p300 acetyltrans-
ferase mutant (27).
The results suggest that AR tran-
scriptional activity is enhanced by
the ability of MAGE-11 to link AR
and p300 by binding the same AR
FXXLF motif required to mediate
the AR N/C interaction. The results
support the notion that AR tran-
scriptional activation by p300 is
mediated through sequential AR
FXXLF motif interactions involving
the AR AF2 site and MAGE-11.
Dependence on p300 Acetyltrans-
ferase Activity—The decrease in the
MAGE-11-dependent GAL-AR-
(16–36) activity with the p300
acetyltransferase mutant led us to
investigate the requirement for
p300 acetyltransferase activity in
the MAGE-11-dependent AR acti-
vity. AR transcriptional activity in
the presence of MAGE-11 or TIF2
alone or together increased with
p300 but not with p300-D1399Y
when assayed using a PSA-Enh-Luc
reporter (Fig. 9A). Similarly, the
p300-dependent increase in GAL-
MAGE-(85–205) and -(140–205)
activity was eliminated with the
p300-D1399Y acetylation mutant
(Fig. 9B).
Because protein stability can be
influenced by acetylation or ubiq-
uitinylation of lysine residues (28),




with FLAG-ubiquitin followed by immunoprecipitation using a
FLAG-affinity resin demonstrated the ubiquitinylation of
MAGE-11 (Fig. 9C) as reported previously (7). Coexpression of
p300 or the p300-D1399Y acetyltransferase mutant inhibited
the ubiquitinylation of MAGE-(112–429). However, there was
no evidence that MAGE-11 was acetylated by p300 (data not
shown), although acetylated forms of TIF2 and p300 were pres-
ent in the complex with MAGE-11 that were not detected with
p300-D1399Y and MAGE-11 (Fig. 10A). Acetylation of TIF2
was reduced with the coexpression of MAGE-11 and was not
detected with p300-D1399Y (Fig. 10B).
The results indicate that p300 acetyltransferase activity is
required forMAGE-11 and p300 to increase AR transcriptional
activity. Although MAGE-11 was not acetylated by p300 even
though there was evidence for the acetylation of both p300 and
FIGURE 8. MAGE-11 links p300 to AR NH2- and carboxyl-terminal (N/C) interaction-mediated transacti-
vation. A, HeLa cells were transfected with 0.1 g of PSA-Enh-Luc and 50 ng of pCMV-AR-(507–919) with and
without 25 ng of wild-type pCMV-AR-(1–503) or the L26A,F27A (LFAA) mutant, 25 ng of pSG5-MAGE, and 25 ng
of pSG5-HA-p300. Inset, COS cells were transfected with 4 g of pCMV5 empty vector () or pCMV-AR-(1–503)
with wild-type sequence or L26A,L27A (LFAA) mutations. The transblot of cell extracts (30 g of protein/lane)
was probed using AR32 antibody. B, COS cells were transfected using Lipofectamine 2000 with 2 g of pSG5-
HA-p300 and 10 nM nonspecific siRNA-5, 10 nM p300 siRNA 1– 4 or without siRNA. Cell extracts were prepared
in immunoblot lysis buffer and probed on a transblot (15 g of protein/lane) using p300 and -actin antibod-
ies. C, HeLa cells (1.2  105/well in 6-well plates) were transfected using Lipofectamine 2000 with 0.1 g of
PSA-Enh-Luc, 50 ng of pCMV-AR-(507–919), 25 ng of pCMV-AR-(1–503), and 25 ng of pSG5-MAGE without
siRNA or with 5 nM nonspecific siRNA-5 (NS5) or p300 siRNA 1– 4. Cells were incubated for 24 h in serum-free
media with and without 10 nM DHT. D, upper panel, COS cells were transfected with 4 g of pSG5 empty vector
() and the indicated pSG5-MAGE vectors. The transblot of cell extracts (30 g of protein/lane) was probed
using FLAG-MAGE-11 antibody-1. Lower panel, HeLa cells were transfected with 0.1 g of PSA-Enh-Luc, 50 ng
of pSG5 empty vector (), WT pSG5-HA-p300, or D1399Y (DY) acetylation mutant, 15 ng of WT or the indicated
pSG5-MAGE mutant, and 0.1 g of GAL-AR-(16 –36) or L26A,F27A (LFAA) mutant. Inset, COS cells were trans-
fected with 6 g of GAL0 empty vector () or GAL-AR-(16 –36) wild-type sequence or L26A,L27A (LFAA) muta-
tions. Cells were treated with 1 M MG132 for 24 h and again 1 h prior to harvest. The transblot of cell extracts
(60 g of protein/lane) was probed using GAL antibody.
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TIF2, p300 inhibited MAGE-11 ubiquitinylation independent
of p300 acetyltransferase activity, and MAGE-11 had an inhib-
itory effect on TIF2 acetylation.
p300 Increases Endogenous MAGE-11 Levels and Is Associ-
ated with an Androgen-responsive Enhancer—Evidence that
p300 inhibits the ubiquitinylation of MAGE-11 (Fig. 9C) raised
the possibility that p300 might influence endogenous MAGE-
11 levels. To pursue this further, p300 was expressed in COS
cells, and protein levels were determined at the indicated times
in serum-free medium. Endogenous MAGE-11 was not
detected without the coexpression of p300 but was evident in a
time-dependent manner when p300 was expressed (Fig. 11A).
Highest levels of MAGE-11 occurred at 7 h and declined sub-
sequently as p300 levels decreased.
The time- and p300-dependent
transient increase in endogenous
MAGE-11 suggested that p300
influences the cell cycle expression
of MAGE-11.
To obtain evidence that endoge-
nous p300 is associatedwith AR and
MAGE-11 at an androgen-respon-
sive gene enhancer, ChIP assays
were performed using LAPC-4
prostate cancer cells that express
AR, MAGE-11, p300, and increased
levels of PSA in response to andro-
gen. The extent of amplified DNA
using PSA upstream enhancer-
specific primers indicated an
increased association of AR, p300,
and MAGE-11 in the presence of
10 nM DHT.
DISCUSSION
AR Transcriptional Regulation by
MAGE-11 and p300—We have demonstrated transcriptional
synergy between AR, the AR coregulator MAGE-11, and
p300, a ubiquitous and potent transcriptional regulator and
acetyltransferase (22, 29, 30). MAGE-11 links the NH2-ter-
minal regions of AR and p300 and increases AR transcrip-
tional activity dependent on p300 acetyltransferase activity.
A transcription complex involving AR, MAGE-11, p300, and
TIF2 was mediated through FXXLF-like motif interactions.
The AR FXXLF motif functions in the androgen-dependent
AR N/C interaction (1, 2) and binds MAGE-11 (Fig. 1) (1, 5).
The MAGE-11-dependent link between AR and p300 was
evident from the transcriptional activity of NH2- and car-
FIGURE 9. Dependence of AR transcription activity on p300 acetyltransferase activity. A, CV1 cells were transfected with 0.1 g of pCMV-AR and 3 g of
PSA-Enh-Luc in the absence and presence of 1 g of pSG5-MAGE, 2 g of pSG5-TIF2, and 2 g of WT pSG5-HA-p300 or D1399Y acetyltransferase mutant (DY).
Cells were incubated for 48 h in the absence and presence of 1 nM DHT. B, HeLa cells were transfected with 0.1 g/ml 5GAL4Luc3 and 0.05 g of GAL-MAGE-
(85–205) or -(140 –205) with 0.15 g of pSG5 empty vector (),WT pSG5-HA-p300, or D1399Y mutant (DY). Lower panel, expression levels were determined in
COS cells transfected with 5 g of pSG5 empty vector () (lane 1), WT pSG5-HA-p300 (lane 2), and D1399Y acetyltransferase mutant (lane 3). Cell extracts (30
g/lane) on the transblot were probed using p300 antibody. C, inhibition of MAGE-11 ubiquitinylation by p300 and p300-D1399Y was demonstrated in COS
cells transfected with 6 g of FLAG empty vector or FLAG-ubiquitin (Ub) and 3 g of pSG5-HA-MAGE-(112– 429) in the absence and presence of 5 g of
pSG5-HA-p300 or the D1399Y acetyltransferase mutant. Cells were incubated in the absence and presence of 0.1 g/ml EGF and immunoprecipitated using
anti-FLAG M2 affinity resin. The transblot was probed with hemagglutinin (HA) antibody.
FIGURE 10. MAGE-11 influences p300 acetylation of TIF2. A, coimmunoprecipitation of acetylated TIF2 and
p300 with FLAG-MAGE was performed in COS cells transfected with 4 g of FLAG empty vector () or FLAG-
MAGE in the absence and presence of 5 g of pSG5 empty vector () or pSG5-TIF2, and 5 g of WT pSG5-HA-
p300 or D1399Y mutant. Cells were incubated with 0.1 g/ml EGF for 24 h prior to harvest and with 5 mM
nicotinamide 1 h prior to harvest. Cell extracts prepared in IP lysis buffer containing 5 mM nicotinamide were
immunoprecipitated overnight at 4 °C. Immunoprecipitates and cell extracts (50 g of protein/lane) were
probed using FLAG, p300, TIF2, and acetylated lysine antibodies. B, inhibition of p300-mediated acetylation of
TIF2 by MAGE-11 was determined by expressing 5 g of FLAG empty vector () or FLAG-TIF2 with 5 g of pSG5
empty vector (), pSG5-HA-p300, or D1399Y mutant with and without 1 g of pSG5-MAGE. Cells were incu-
bated in serum-free media with 0.1 g/ml EGF for 24 h prior to harvest and with 5 mM nicotinamide and 5 mM
sodium butyrate for 1 h prior to harvest in IP lysis buffer containing 5 mM nicotinamide and 5 mM sodium
butyrate. Immunoprecipitates and cell extracts (30 g of protein/lane for p300, 50 g/lane for acetylated
lysine, 70 g/lane for FLAG-TIF2 and MAGE-11) were probed on transblots using antibodies for FLAG-MAGE-11,
FLAG, and TIF2, p300, and acetylated lysine.
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boxyl-terminal AR fragments that depend on the AR N/C
interaction and by the increase in activity of GAL-AR-(16–
36), an AR FXXLF motif fusion peptide.
The findings suggest that the AR FXXLF motif mediates an
increase in AR transcriptional activity not only through its
interaction with AF2 in the AR N/C interaction but also by
recruiting MAGE-11, which in turn interacts with the NH2-
terminal region of p300. The critical function of the AR N/C
interaction is supported by AR AF2 site mutations that disrupt
AR FXXLF motif binding and AR function (19). The studies
support the supposition that a single interaction motif under-
goes multiple transient interactions during the process of AR-
mediated transcription. Dependence of androgen-responsive
enhancer/promoters on the AR NH2-terminal FXXLF motif
(25) may be explained by multiple FXXLF motif-mediated
interactions that lead to recruitment of p300. It is noteworthy
that the reported ability of p300 to increase AR transcriptional
activity made use of prostate cancer cell lines (31) that have
relatively higher levels of AR and MAGE-11.
Interaction sites for FXXLF-related motifs can also serve
multiple functions that differ in specificity. For example, the
AF2 site in the AR ligand binding domain binds the AR NH2-
terminal FXXLFmotif, p160 coactivator LXXLLmotifs (Fig. 1),
and FXXLF-related motifs in putative AR coactivators (25, 32),
but it does not bind the p300 NH2-terminal FXXLF motif (18).
In contrast, theMAGE-11 F-box binds theARFXXLFmotif but
does not bind several FXXLF motifs present in putative AR
coactivators (6) or in p300. The MAGE-11 F-box was required
to increase the activity of GAL-p300-(2–300) through a mech-
anism that remains to be established. The MAGE-11 F-box at
amino acid residues 329–369 begins with the sequence
329IPEE332 followed by a conserved arrangement of hydropho-
bic amino acid residues similar to the F-box of cyclin F (6). p300
contains a similar 43LPDE46 sequence positioned close to the
33FGSLF37 FXXLF motif but with a different arrangement of
hydrophobic residues than the MAGE-11 F-box. Deletion of
this putative p300 F-box region in GAL-p300-(48–200)
increased the interaction with full-length AR and was influ-
enced by the AR FXXLF motif. This suggested that an F-box-
like sequence in the NH2-terminal region of p300 may interact
with another protein that competes with AR binding to p300.
The existence of multiple overlapping motifs and binding sur-
faces is consistent with MAGE-11 and p300 coordinating tem-
poral interactions during AR transactivation.
Both MAGE-11 and p300 are downstream targets of MAPK
(6, 33) and p300 is phosphorylated in a time-dependentmanner
in response to EGF (34). In response to serum stimulation,
MAGE-11 is phosphorylated byMAPK at Ser-174, a conserved
residue in the MAGE-A subfamily (6). The MAGE-S174A
mutant eliminated the functional interaction between
MAGE-11 and p300 that was restored with the S174D phos-
phomimetic. The MAGE-11 S174A mutation also diminished
the MAGE-11 interaction with the AR FXXLF motif (6). Inhi-
bition of GAL-p300 activity by MAGE-S174A suggests that
phosphorylation influences the ability of p300 to function with
MAGE-11 to modulate AR transcriptional activity. The results
suggest that MAPK phosphorylation at Ser-174 regulates sev-
eral important aspects of MAGE-11 function.
Requirement for p300 Acetyltransferase Activity—p300 has a
modular structure of protein interaction sites. These include a
cysteine- and histidine-rich Taz1 domain at residues 332–417,
a Kix domain (residues 566–646) that interacts with CBP-
binding protein CREB, a Bromo domain that interacts with p53
(residues 1053–1156), a PHD domain (residues 1198–1278), a
glutamine-rich carboxyl-terminal region that interacts with the
p160 coactivator activation domain-1 (14, 35, 36), and a lysine
acetyltransferase domain between amino acid residues 1284
and 1517 (22).
The NH2-terminal region of p300 was implicated previously
in ligand-dependent nuclear receptor signaling, although the
interaction sites were not defined (10, 37). The closely related
cyclicAMP-response element-binding protein-binding protein
(CBP) (10, 29) mediated ligand-independent effects of the AR
NH2-terminal region through the CBP 271–452-amino acid
region (31), and the CBP steroid receptor coactivator 1 (SRC1)
interaction domain carboxyl-terminal residues 2058–2130
interact with SRC1 activation domain 1 (AD1) residues 926–
960 conserved among p160 coactivators (36, 38).We found that
the ability ofMAGE-11 and p300 to increaseAR transcriptional
activity depended on the p300 NH2-terminal FXXLF motif
sequence 33FGSLF37. However, the p300 FXXLF motif did not
interact directly with MAGE-11 but was required for a func-
tional interaction with the NH2-terminal region of TIF2, and
for the MAGE-11-dependent increase in GAL-p300 transcrip-
tional activity.
p300 acetyltransferase activity has multiple targets that in-
clude acetylation of histone tail lysine residues that open the
chromatin structure for active transcription. p300 also acety-
lates non-histone proteins such as p160 coactivators, p53 and
-catenin (29, 39–42). TIF2 was reported to be acetylated by
CBP, and the p160 activator for thyroid hormone and retinoid
receptors ACTR was acetylated by p300, which modulated the
interaction of activator for thyroid hormone and retinoid
receptors with nuclear receptors (43). p300 acetyltransferase
activity was also linked to AR signaling. AR was acetylated at
FIGURE 11. Transient increase and chromatin association of endogenous
MAGE-11. A, COS cells were transfected with 6 g of pSG5-HA-p300 or pSG5
empty vector and the next day transferred to serum-free phenol red-free
medium and 24 h later to fresh serum-free medium. Cells were harvested at
the indicated times, and cell extracts were prepared in immunoblot lysis
buffer, and 40 g of protein/lane were analyzed on a transblot probed using
p300 antibody and 10 g/ml each of MAGE-11 antipeptide antibodies 13–26,
59 –79, and 94 –108. B, ChIP analysis of AR, p300, and MAGE-11 at the PSA
androgen-responsive enhancer was performed in LAPC-4 cells incubated for
24 h with and without 10 nM DHT and cross-linked using formaldehyde. Son-
icated DNA was immunoprecipitated using 10 g of normal rabbit IgG (lanes
2 and 3), AR H-280 (lanes 4 and 5), p300 (lanes 6 and 7), and MAGE-11 antibod-
ies (lanes 8 and 9), with a no template control (lane 1).
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Lys-632 and -633 by p300 and p/CAF, a p300-associated pro-
tein (44). However, these basic residues are part of the AR
bipartite nuclear targeting signal (45) so that inhibitory effects
on AR nuclear transport may complicate interpretation of the
consequences of acetylation onAR transcriptional activity. The
dependence of MAGE-11 on p300 acetyltransferase activity to
increase AR transcriptional activity was associated with the
acetylation of p300 and TIF2.
Protein stability and function are influenced by the compet-
ing and complementary effects of acetylation and ubiquitinyla-
tion at lysine residues (28). For example, p300 regulates the
levels of p53 by promoting p53 degradation through an associ-
ation with the MDM2 E3-like ubiquitin ligase (46). Although
MAGE-11 was not acetylated by p300, p300 inhibited
MAGE-11 ubiquitinylation through an acetylation-indepen-
dent mechanism. The transient increase in endogenous
MAGE-11 when p300 was expressed appeared to be cell cycle-
regulated, in agreement with evidence that MAGE-11 is cell
cycle-regulated in CWR-R1 prostate cancer cells (6).
MAGE-11 is monoubiquitinylated at Lys-240 and -245 and
undergoes polyubiquitinylation in association with its degrada-
tion (7). Although the E3 ligase that ubiquitinates MAGE-11
has not been identified, some evidence suggests that MAGE-
11 itself functions as part of a ubiquitin ligase complex.
MAGE-11 contains an F-box similar to the F-box in S-phase
kinase-associated protein 2 (Skp2) and MAGE-11 interacted
with Skp1 (6). p300 was reported to have E4 ubiquitin ligase
activity (47) that could influence the ubiquitinylation of
MAGE-11.
A Primate-specific AR Transcriptional Scaffold—The evolu-
tion ofMAGE-11 has resulted in its exclusive expressionwithin
the primate lineage. This suggests a novel mechanism has
arisen in primates to increase AR signaling that is facilitated by
interactions between AR, MAGE-11, p300, and p160 coactiva-
tors. MAGE-11 may function as a transcription factor scaffold
assembly protein for AR. A similar function as a transcription
factor nucleation site has been attributed to p300 that may
increase gene expression at select enhancers by bridging
betweenDNA-binding nuclear receptors and transcription fac-
tors to the basal transcriptional machinery (48, 49). Many tran-
scription factors, nuclear receptors, and signaling proteins
interact with p300, and the levels of p300 are thought to be
rate-limiting for transcription (50). Competition may exist in
recruiting p300 to nuclear receptor-regulated enhancers. Inter-
action between MAGE-11 and p300 could enhance AR-medi-
ated gene regulation through the more efficient recruitment of
a limiting set of proteins that include p300, p160 coactivators,
and components of the general transcriptional machinery.
p300 and CBP were shown to increase androgen-dependent
and ligand-independent AR transactivation in prostate cancer
(44, 51, 52). However, p300 protein levels decrease in prostate
cancer cells in response to androgen (53), and p300 mRNA
levels were unchanged in the CWR22 human prostate cancer
xenograft during tumor progression to castration-recurrent
growth when AR mRNA levels increase 5-fold (9). In con-
trast,MAGE-11mRNA levels increased50-fold in the castra-
tion-recurrent CWR22 tumor, and up to 1000-fold in a subset
of castration-recurrent prostate cancer tissue specimens. The
increase in MAGE-11 in castration-recurrent prostate cancer
provides a mechanism for AR to more effectively recruit p300
and TIF2 and increase transactivation of AR target genes when
circulating androgen levels are low.
MAGE-11 and the Adenovirus Early Protein, E1A—p300 was
first identified based on its interactionwith the adenovirus early
oncoprotein E1A that targets p300 during viral infection (31,
35, 54, 55). Sequence similarity between the NH2-terminal
regions of MAGE-11 and E1A suggested that MAGE-11 may
share properties of E1A and interact with p300. Binding to E1A
decreased p300 transcriptional activity through the modifica-
tion of histone acetyltransferase activity (35, 56–58).MAGE-11
does not interact with the histone acetyltransferase domain of
p300 but inhibits p300 acetylation of TIF2. Inhibition of p300
histone acetyltransferase activity was also associated with p300
phosphorylation at Ser-89 (59), suggesting that allosteric effects
extend from the p300 NH2-terminal region that could be influ-
enced by MAGE-11.
E1A has a modular structure of interaction motifs for tran-
scriptional regulators associated with the induction of the
S-phase of the cell cycle, cell immortalization, cell transforma-
tion, and transcriptional regulation (60–62). Based on evi-
dence that E1A binds p300 and promotes cell growth, it was
suggested that p300 functions as a tumor suppressor (29).
The E1A FX(D/E)XXXL motif sequence 66FPDSVML72 was
reported to interact with one of several domains in p300/CBP
(63). MAGE-11 contains a similar FX(D/E)XXXL motif se-
quence 66FREQANL72 at the same relative position to the NH2
terminus as E1A. However, single amino acid mutations in the
MAGE-11 FX(D/E)XXXL motif did not interfere with p300
binding (data not shown), suggesting that other MAGE-11
regions possibly homologous to E1A bind p300 (60). Instead,
interaction between MAGE-11 and p300 depended on the
MAGE-11 MXXIF motif 185MDAIF189 (Fig. 1) and secondarily
on IXXIF motif 94ITQIF98, as well as the MAGE-11 F-box and
MAPK phosphorylation. The MAGE-11 185MXXIF189 motif
and Ser-174MAPK site are in close proximity and homologous
to a region in E1A. The reported E1A 66FX(D/E)XXXL72 inter-
action site for p300 is preceded by 62VSQIF66 which, based on
sequence homology and position, could be a previously unrec-
ognized E1A interaction site for p300.
Although there are no known human genomic counterparts
for E1A, sequence similarity between MAGE-11 and E1A sug-
gests that MAGE-11 shares some functional properties with
E1A. The late evolutionary species-specific divergence of the
MAGE gene family among primates suggests that like E1A,
MAGE-11 may have hijacked transcription factor binding sites
required for its function as an AR-selective coregulator.
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